J&J’s Velcade Is Not Cost-Effective For Multiple Myeloma, U.K.’s NICE Suggests
A National Institute for Health & Clinical Excellence analysis finds cost per quality-adjusted life year gained as high as $83,000.
A National Institute for Health & Clinical Excellence analysis finds cost per quality-adjusted life year gained as high as $83,000.